The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding
Open accessAbstract
The soluble interleukin 6 receptor (sIL-6R) circulates at elevated levels in various diseases. This suggests that inflammatory mediators control sIL-6R release. Through examination of human neutrophils, it was found that the acute phase reactant C-reactive protein (CRP) activates a threefold increase in sIL-6R production. Maximal release occurred after 30–60 min exposure to CRP (50 μg/ml), and was mimicked by peptides corresponding to amino acid residues 174– 185 and 201–206 of native CRP. A third peptide fragment (77–82) had no effect. Differential mRNA splicing did not account for the CRP-mediated release of sIL-6R, since this isoform was not detected in conditioned media. Furthermore, stimulation of neutrophils with CRP or with peptides 174–185 or 201–206 promoted a loss of membrane-bound IL-6R, suggesting release by proteolytic shedding. The metalloprotease inhibitor TAPI had only a marginal effect on CRP-mediated sIL-6R release, suggesting that shedding occurs via a mechanism distinct from that previously reported. It well established that IL-6 stimulates the acute phase expression of CRP. Our current findings demonstrate a novel relationship between these two mediators, since CRP may affect IL-6–mediated inflammatory events by enabling formation of the sIL-6R/IL-6 complex.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 1×
“T he receptor complex that mediates the biological activities of IL-6 consists of two distinct membranebound glycoproteins, an 80-kD cognate receptor subunit (IL-6R, CD126) and a 130-kD signal transducing element (gp130) (1).”
Background
Cited by
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Self-citationAtreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
Walston, J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.20.2333 · Cited by 940
“Serum levels of CRP increase in response to acute or chronic illness and inflammatory states.(13,17,19) While its exact role remains controversial, CRP may act to amplify both inflammation and clotting through a number of pathways.”
BackgroundHuman C-reactive protein: expression, structure, and function
Volanakis, J. (2001) · Molecular Immunology · doi:10.1016/s0161-5890(01)00042-6 · Cited by 926
Sack, D. A., Sack, R. B., Nair, G. B., & Siddique, A. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15328-7 · Cited by 905
Hurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811
Self-citationIs obesity an inflammatory condition?
Das, U. N. (2001) · Nutrition · doi:10.1016/s0899-9007(01)00672-4 · Cited by 799
Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6
Jones, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3463 · Cited by 771
Self-citationInterleukin-6 in Aging and Chronic Disease: A Magnificent Pathway
Maggio, M., Guralnik, J. M., Longo, D. L., & Ferrucci, L. (2006) · The Journals of Gerontology: Series A · doi:10.1093/gerona/61.6.575 · Cited by 692
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose-John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683
Self-citationIto, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Verma, S., Li, S.-H., Badiwala, M. V., Weisel, R. D., Fedak, P. W. M., Li, R.-K., Dhillon, B., & Mickle, D. A. G. (2002) · Circulation · doi:10.1161/01.cir.0000015126.83143.b4 · Cited by 634
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
JONES, S. A., HORIUCHI, S., TOPLEY, N., YAMAMOTO, N., & FULLER, G. M. (2001) · The FASEB Journal · doi:10.1096/fj.99-1003rev · Cited by 623
Self-citationIl-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance
Mudter, J., & Neurath, M. F. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20148 · Cited by 436
Interleukin-6 ( IL-6 ) and the Prognosis of Abdominal Aortic Aneurysms
Jones, K. G., Brull, D. J., Brown, L. C., Sian, M., Greenhalgh, R. M., Humphries, S. E., & Powell, J. T. (2001) · Circulation · doi:10.1161/01.cir.103.18.2260 · Cited by 369
Fitzgerald, M. L., Wang, Z., Park, P. W., Murphy, G., & Bernfield, M. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.4.811 · Cited by 367
Chalaris, A., Rabe, B., Paliga, K., Lange, H., Laskay, T., Fielding, C. A., Jones, S. A., Rose-John, S., & Scheller, J. (2007) · Blood · doi:10.1182/blood-2007-01-067918 · Cited by 329
Self-citationInvolvement of IL–6 in the pathogenesis of inflammatory bowel disease and colon cancer
Atreya, R., & Neurath, M. F. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:3:187 · Cited by 324
Interleukin 6 as an Energy Allocator in Muscle Tissue
Kistner, T. M., Pedersen, B. K., & Lieberman, D. E. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00538-4 · Cited by 295
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Chalaris, A., Garbers, C., Rabe, B., Rose-John, S., & Scheller, J. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.10.007 · Cited by 289
Nowell, M. A., Richards, P. J., Horiuchi, S., Yamamoto, N., Rose-John, S., Topley, N., Williams, A. S., & Jones, S. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3202 · Cited by 268
Self-citationJones, S. A., & Rose-John, S. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00319-1 · Cited by 255
Self-citationT cells in systemic sclerosis: a reappraisal
O'Reilly, S., Hugle, T., & van Laar, J. M. (2012) · Rheumatology · doi:10.1093/rheumatology/kes090 · Cited by 218
Ekinci, O., & Ekinci, A. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1363285 · Cited by 122
Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration
Peters, M., Blinn, G., Jostock, T., Schirmacher, P., Büschenfelde, K. M. Z., Galle, P. R., & Rose–John, S. (2000) · Gastroenterology · doi:10.1053/gast.2000.20236 · Cited by 129
Galun, E., Zeira, E., Pappo, O., Peters, M., & Rose-John, S. (2000) · The FASEB Journal · doi:10.1096/fj.99-0913com · Cited by 124
“, haptoglobin), and these proteins have recently been found to induce the shedding of IL-6R from macrophages (35).”
BackgroundSleep enhances IL‐6 trans‐signaling in humans
Dimitrov, S., Lange, T., Benedict, C., Nowell, M. A., Jones, S. A., Scheller, J., Rose‐John, S., Born, J., Dimitrov, S., Lange, T., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-5754fje · Cited by 115
Self-citationImpact of interleukin-6 classic- and trans-signaling on liver damage and regeneration
Drucker, C., Gewiese, J., Malchow, S., Scheller, J., & Rose-John, S. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.08.003 · Cited by 83
Metadata
- Authors
- Jones, S. A., Novick, D., Horiuchi, S., Yamamoto, N., Szalai, A. J., & Fuller, G. M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1999-02-01
- Volume
- 189
- Issue
- 3
- Pages
- 599-604
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2148463512
- Cited by
- 196
- References
- 1
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.